Neonatal lupus erythrematosus overview: Difference between revisions
Jump to navigation
Jump to search
Mahmoud Sakr (talk | contribs) |
Mahmoud Sakr (talk | contribs) No edit summary |
||
| Line 9: | Line 9: | ||
==Pathophysiology== | ==Pathophysiology== | ||
==Differentiating | ==Differentiating Neonatal Lupus Erythrematosus from Other Diseases== | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
Revision as of 22:06, 23 August 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mahmoud Sakr, M.D. [2]
Overview
Neonatal lupus erythrematosus is an autoimmune disease that results from passive transfer of autoantibodies from the mother to the fetus. It occurs in about 1 to 2 percent of babies born to mothers with autoimmune disease, primarily systemic lupus erythematosus and Sjögren’s syndrome, and antibodies to SSA/Ro and/or SSB/La.[1][2].
Pathophysiology
Differentiating Neonatal Lupus Erythrematosus from Other Diseases
Epidemiology and Demographics
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
EKG
Echocardiography
Treatment
Medical Therapy
Surgery
References
- ↑ Brucato A, Cimaz R, Caporali R, Ramoni V, Buyon J (2011). "Pregnancy outcomes in patients with autoimmune diseases and anti-Ro/SSA antibodies". Clin Rev Allergy Immunol. 40 (1): 27–41. doi:10.1007/s12016-009-8190-6. PMC 3558034. PMID 20012231.
- ↑ Buyon JP (2009). "Updates on lupus and pregnancy". Bull NYU Hosp Jt Dis. 67 (3): 271–5. PMID 19852749.